1. Scrip
  2. >>Advanced Therapies
  3. >>Gene Therapies

Prime Medicine Launches With $315m To Fund New Approach To Gene Editing

 
• By Alaric DeArment

The company sees its gene-editing technology, which it compares to a DNA “word processor,” as having potentially broad applicability.

DNA helix
Gene-editing company Prime Medicine launches with $315m in financing from two funding rounds • Source: Shutterstock

Newly launched Prime Medicine foresees its gene-editing technology platform has having potentially even broader utility than other technologies in development, like CRISPR/Cas9 and base editing, and has its eye on four sets of indications to try it in.

The Cambridge, MA-based company announced its official launch 13 July, with $315m in financing that includes a $115m series A round that it raised at the end of 2019 and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

More from Advanced Therapies

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

 
• By Alaric DeArment

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.